BMS 986406
Alternative Names: BMS-986406; ONO-7226Latest Information Update: 10 Oct 2024
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; LILRB2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 16 Aug 2024 Bristol-Myers Squibb completes a phase I trial in Solid tumours (Monotherapy, Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Spain, South Korea, Japan, Belgium, Argentina (Parenteral) (NCT05298592) (EudraCT-2021-006872-17)
- 31 Mar 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (Parenteral) (NCT05298592)
- 31 Mar 2022 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (Parenteral) (NCT05298592)